Toyohiro Hirai

Kyoto University
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Backgrounds Fibrosis may coexist with emphysema in chronic obstructive pulmonary disease (COPD), but computed tomography (CT) quantification is challenging. Persistent homology (PH), a topological data analysis technique, provides interpretable structural features in grayscale images. By using PH, this CT study aimed to quantify fibrotic lesions in nonemphysematous and emphysematous lungs and to investigate clinical implications of PH-based fibrosis quantification in patients with COPD. Methods The study included subjects from the Lung Cancer Screening (LCS) cohort (n=346) and two prospective COPD cohorts (Kyoto University [KU], n=234; Kyoto-Himeji, n=166). Based on CT value patterns and spatial topology, PH assigned each voxel as fibrotic or non-fibrotic and calculated the percentage of fibrotic lung volume (PH-fibrosis%) in association with visually identified interstitial lung abnormality (ILA) and COPD outcomes. Results Higher PH-fibrosis% was associated with ILAs in the LCS and KU cohorts. The two COPD cohorts consistently showed significant associations between higher baseline PH-fibrosis% and future exacerbation risk independent of emphysema and airway wall thickness (hazard ratios [HR]: 1.39 and 3.35 for KU and Kyoto-Himeji, respectively). In the KU cohort, higher PH-fibrosis% was significantly associated with increased mortality (HR: 1.94), with a similar trend in the Kyoto-Himeji cohort (HR: 1.86). Longitudinal increases in PH-fibrosis% over median 4.98 years were associated with higher exacerbation frequency and patients experiencing greater increase in PH-fibrosis% subsequently exhibited higher mortality in the KU cohort. Conclusions PH can be used to quantify fibrotic lesions on CT and PH-fibrosis% could be a prognostic imaging marker in patients with COPD.

Year:

2026

Background Frailty often coexists in patients with chronic obstructive pulmonary disease (COPD) regardless of disease severity and may serve as a treatable trait. We hypothesized that factors associated with frailty may differ by COPD severity. This study aimed to comprehensively explore related factors including symptoms, physical activity, dietary behavior, serum biomarkers, and CT parameters. Methods This cross-sectional analysis of a multicenter prospective cohort study included patients with COPD aged ≥50 years with a smoking history ≥10 pack-years. Frailty was assessed using the Kihon Checklist. Data were collected using questionnaires on symptoms, physical activity, and dietary behavior, as well as blood tests and CT parameters. Associations between frailty and clinical variables were assessed using multivariable linear and logistic regressions in all patients and within the COPD severity subgroups. Results Among 225 patients, 45 (20%) were diagnosed with frailty. These patients were older, more likely to have cardiovascular disease (CVD), and had a higher neutrophil-to-lymphocyte ratio. Stratified by COPD severity, age, forced expiratory volume in 1 s (FEV 1 ), and calorie intake did not differ by frailty status, whereas patients with frailty exhibited more severe symptoms. In multivariable analysis, frailty was associated with social factors (living alone, unemployment), comorbidities (CVD, gastroesophageal reflux disease), and CT airway parameters (WA%), but not emphysema, independent of FEV 1 . Furthermore, living alone was linked to frailty in mild COPD. Conclusion Social factors, comorbidities, and WA% were associated with frailty in patients with COPD. Social factors were more relevant in patients with mild COPD.

Year:

2025

Background Chronic respiratory failure (CRF) is a critical complication in patients with chronic obstructive pulmonary disease (COPD) and is characterized by an increase in the arterial-alveolar oxygen gradient (A-aDO 2 ). The long-term trajectory and prognostic significance remain unclear. This study aimed to assess the prognostic impact of A-aDO 2 and elucidate its trajectory over ten years. Methods We enrolled 170 outpatients with COPD from a prospective cohort study. Arterial blood gas (ABG) analyses were conducted annually for ten years while monitoring the development of CRF. Results 157 patients completed the observation period, of whom 21 developed CRF (CRF group) and 136 did not (non-CRF group). In the CRF group, there was a gradual increase in A-aDO 2 along with decreases in partial pressure of oxygen (PaO 2 ) and partial pressure of carbon dioxide (PaCO 2 ) over ten years, although there were no changes in the non-CRF group. The CRF group had higher baseline A-aDO 2 and higher ΔA-aDO 2 in the first year than the non-CRF group (3.76 vs. 0.42 Torr/year, p = 0.030). Kaplan-Meier analyses, and multivariate Cox proportional hazards analysis revealed that both baseline A-aDO 2 and ΔA-aDO 2 were significantly associated with the development of CRF. Retrospective tracking from the initiation of long-term oxygen therapy (LTOT) revealed significant increases in A-aDO 2 from 5 years prior to LTOT initiation in the CRF group when compared to the non-CRF group. Conclusions An increasing trend in A-aDO 2 may be a significant sign for the future development of CRF. A transition of the annual change of A-aDO 2 from a stable state to a deterioration phase can serve as a prognostic factor for developing CRF within 5 years.

Year:

2025

Background Dipeptidyl peptidase 1 (DPP1) exacerbates airway neutrophilic inflammation in bronchiectasis, which is characterised by airway dysfunction and dilation and chronic bacterial infection. However, little is known about the pathogenetic roles of DPP1 in obstructive airway diseases, including COPD, asthma and asthma–COPD overlap (ACO). Here, we tested the hypothesis that airway DPP1 could enhance neutrophilic inflammation and affect mucus plugging, airway dilation and the airway microbiome in patients with these diseases. Methods Sputum DPP1, cell differential count and microbiome were cross-sectionally evaluated in patients with COPD, asthma with airflow limitation and ACO. Sputum high mobility group box 1 (HMGB1) was measured to estimate airway epithelial damage. Chest computed tomography was also performed to visually assess mucus plugs and airway dilation with the Reiff score and quantify the total airway count and wall area percentage. Results 68 patients were classified into high-DPP1/high-neutrophil (n=17), low-DPP1/high-neutrophil (n=37) and low-neutrophil (n=14) groups based on sputum DPP1 levels and neutrophil percentages. The rate of mucus plugging and the relative abundance of the phylum Firmicutes were significantly lower and the level of sputum HMGB1 was significantly greater in the high-DPP1/high-neutrophil group than in the low-DPP1/high-neutrophil group. Moreover, airway dilation without mucus plugging was observed only in the high-DPP1/high-neutrophil group (prevalence 29%). Conclusions High sputum DPP1 levels may reduce colonisation by the phylum Firmicutes and mucus plugging, but increase airway epithelial damage, which could induce airway dilation without mucus plugging in patients with obstructive airway disease with neutrophilic inflammation.

Year:

2024

Background Asthma is a heterogeneous disease with variable response to treatment. Genetic backgrounds are involved in the severity of type 2 asthma, but their effects on responses to biologics remain unknown. This study aimed to clarify the role of genetic factors in response to biologics in patients with severe asthma. Methods Adults with severe asthma receiving biologics were enrolled in this multicentre, observational, real-world study. The responses to biologics were evaluated using Physicians’ Global Evaluation of Treatment Effectiveness (GETE). Optimal biologic for each patient was also determined based on the best GETE score for the biologic used or currently used biologic. Three single nucleotide polymorphisms ( IL1RL1 , rs1420101; IL4RA , rs8832; and TSLP rs1837253) were examined. Results Among the 113 patients analysed, 53 (46.9%) had an excellent GETE score for at least one biologic. These patients with an excellent GETE score for at least one biologic, particularly for benralizumab, had the risk genotype of rs1420101 more frequently than the remaining patients, independent of the clinical demographics. Regarding the optimal biologic for each patient, anti-IL-5 drugs were optimal for patients with the rs1420101 TT or rs8832 GG genotype. Furthermore, dupilumab was similarly effective, regardless of the risk genotypes examined in this study. Conclusion IL1RL1 rs1420101 TT genotype and/or IL4RA rs8832 GG genotype may predict an excellent or optimal response to biologic therapy in each patient, particularly to anti-interleukin-5 targeted therapy. The elucidation of genetic predisposition may improve the management of severe asthma in the era of biologics.

Year:

2024

Background and Objective Mucus plugs and underlying airway tree structure can affect airflow limitation and prognosis in patients with chronic obstructive pulmonary disease (COPD), but their relative roles are unclear. This study used two COPD cohorts to examine whether mucus plugs on computed tomography (CT) were associated with airflow limitation and clinical outcomes independent of other airway structural changes and emphysema. Methods Based on visual CT assessment, patients with mucus plugs in 0, 1–2 and ≥3 lung segments were assigned to no‐, low‐ and high‐mucus groups. Loss of health‐related independence and mortality were prospectively recorded for 3 and 10 years in the Kyoto–Himeji and Hokkaido cohorts, respectively. The percentages of the wall area of the central airways (WA%), total airway count (TAC) and emphysema were quantified on CT. Results Of 199 and 96 patients in the Kyoto–Himeji and Hokkaido cohorts, 34% and 30%, respectively, had high mucus scores. In both cohorts, TAC was lower in the high‐mucus group than in the no‐mucus group, whereas their emphysema severity did not differ. High mucus score and low TAC were independently associated with airflow limitation after adjustment for WA% and emphysema. In multivariable models adjusted for WA% and emphysema, TAC, rather than mucus score, was associated with a greater rate of loss of independence, whereas high mucus score, rather than TAC, was associated with increased mortality. Conclusion Mucus plugs and lower airway branch count on CT had distinct roles in airflow limitation, health‐related independence and mortality in patients with COPD. image

Year:

2024

EGFR-tyrosine kinase inhibitors (TKI) are the first-line therapies for EGFR mutation–positive lung cancer. EGFR-TKIs have favorable therapeutic effects. However, a large proportion of patients with EGFR mutation–positive lung cancer subsequently relapse. Some cancer cells survive the initial treatment with EGFR-TKIs, and this initial survival may be associated with subsequent recurrence. Therefore, we aimed to overcome the initial survival against EGFR-TKIs. We hypothesized that yes-associated protein 1 (YAP1) is involved in the initial survival against EGFR-TKIs, and we confirmed the combined effect of EGFR-TKIs and a YAP1–TEAD pathway inhibitor. The KTOR27 (EGFR kinase domain duplication) lung cancer cell lines established from a patient with EGFR mutation–positive lung cancer and commercially available PC-9 and HCC827 (EGFR exon 19 deletions) lung cancer cell lines were used. These cells were used to evaluate the in vitro and in vivo effects of VT104, a TEAD inhibitor. In addition, YAP1 involvement was investigated in pathologic specimens. YAP1 was activated by short-term EGFR-TKI treatment in EGFR mutation–positive lung cancer cells. In addition, inhibiting YAP1 function using siRNA increased the sensitivity to EGFR-TKIs. Combination therapy with VT104 and EGFR-TKIs showed better tumor-suppressive effects than EGFR-TKIs alone, in vitro and in vivo . Moreover, the combined effect of VT104 and EGFR-TKIs was observed regardless of the localization status of YAP1 before EGFR-TKI exposure. These results suggest that combination therapy with the TEAD inhibitor and EGFR-TKIs may improve the prognosis of patients with EGFR mutation–positive lung cancer.

Year:

2024

Background Low respiratory function in young adulthood is one of the important factors in the trajectory leading to the future development of COPD, but its morphological characteristics are not well characterised. Methods We retrospectively enrolled 172 subjects aged 40–49 years with ≥10 pack-years smoking history who underwent lung cancer screening by computed tomography (CT) and spirometry at two Japanese hospitals. Emphysema was visually assessed according to the Fleischner Society guidelines and classified into two types: centrilobular emphysema (CLE) and paraseptal emphysema (PSE). Airway dysanapsis was assessed with the airway/lung ratio (ALR), which was calculated by the geometric mean of the lumen diameters of the 14 branching segments divided by the cube root of total lung volume on a CT scan. Results Among the subjects, CLE and PSE were observed in 20.9% and 30.8%, respectively. The mean ALR was 0.04 and did not differ between those with and without each type of emphysema. Multivariable regression analysis models adjusted for age, sex, body mass index and smoking status indicated that CLE and a low ALR were independently associated with lower forced expiratory volume in 1 s (FEV 1 )/forced vital capacity (estimate −1.64 (95% CI −2.68– −0.60) and 6.73 (95% CI 4.24–9.24), respectively) and FEV 1 % pred (estimate −2.81 (95% CI −5.10– −0.52) and 10.9 (95% CI 5.36–16.4), respectively). Conclusions CLE and airway dysanapsis on CT were independently associated with low respiratory function in younger smokers.

Year:

2024

EGFR-tyrosine kinase inhibitors (TKI) are the first-line therapies for EGFR mutation–positive lung cancer. EGFR-TKIs have favorable therapeutic effects. However, a large proportion of patients with EGFR mutation–positive lung cancer subsequently relapse. Some cancer cells survive the initial treatment with EGFR-TKIs, and this initial survival may be associated with subsequent recurrence. Therefore, we aimed to overcome the initial survival against EGFR-TKIs. We hypothesized that yes-associated protein 1 (YAP1) is involved in the initial survival against EGFR-TKIs, and we confirmed the combined effect of EGFR-TKIs and a YAP1–TEAD pathway inhibitor. The KTOR27 (EGFR kinase domain duplication) lung cancer cell lines established from a patient with EGFR mutation–positive lung cancer and commercially available PC-9 and HCC827 (EGFR exon 19 deletions) lung cancer cell lines were used. These cells were used to evaluate the in vitro and in vivo effects of VT104, a TEAD inhibitor. In addition, YAP1 involvement was investigated in pathologic specimens. YAP1 was activated by short-term EGFR-TKI treatment in EGFR mutation–positive lung cancer cells. In addition, inhibiting YAP1 function using siRNA increased the sensitivity to EGFR-TKIs. Combination therapy with VT104 and EGFR-TKIs showed better tumor-suppressive effects than EGFR-TKIs alone, in vitro and in vivo. Moreover, the combined effect of VT104 and EGFR-TKIs was observed regardless of the localization status of YAP1 before EGFR-TKI exposure. These results suggest that combination therapy with the TEAD inhibitor and EGFR-TKIs may improve the prognosis of patients with EGFR mutation–positive lung cancer.

Year:

2023

Collaborators (13)

Hisako Matsumoto

Chief Professor

Kindai University

JAPAN
View details

Tomoko Funazo

Kyoto University Hospital

JAPAN
View details

Takashi Nomizo

Assistant Professor

Kyoto University Hospital

JAPAN
View details

Akihiko Yoshizawa

Kyoto University Hospital

JAPAN
View details

hironori yoshida

Kyoto University Hospital

JAPAN
View details

NAOYA TANABE

Kyoto University Hospital

JAPAN
View details

Shigeo Muro

Professor

Nara Medical University

JAPAN
View details

Hiroaki Ozasa

助教 / Assistant Professor

Kyoto University

JAPAN
View details

Takahiro Tsuji

Fred Hutch Cancer Center

UNITED STATES
View details

Hiroshi Date

Duke University Medical Center

UNITED STATES
View details

Kazutaka Hosoya

Medical Staff

Kyoto University Hospital

JAPAN
View details

Toshi Menju

Associate Professor

Kyoto University

JAPAN
View details

Kaori Ikeda

講師 / Senior Lecturer/ Junior Associate Professor

Kyoto University

JAPAN
View details